• Home
  • Latest
    • News
    • North America
    • Europe
    • Asia
    • Middle East
    • Global
  • Coins2Day 500
    • Coins2Day 500 U.S.
    • Coins2Day Global 500
    • Coins2Day 500 Europe
    • Coins2Day China 500
    • Coins2Day SEA 500
  • Finance
    • Economy
    • Banking
    • Personal Finance
    • Investing
    • Real Estate
    • Energy
    • Crypto
  • Tech
    • Big Tech
    • Startups & Venture
    • AI
    • Innovation
    • Cybersecurity
  • Leadership
    • Future Of Work
    • Success
    • C-Suite
    • Workplace Culture
    • CEO Initiative
  • Lifestyle
    • Arts & Entertainment
    • Health
    • Travel & Leisure
    • Education
  • Rankings
    • Great Place To Work
    • Analytics
  • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Press Releases
    • Video
    • Podcasts
  • Home
  • Latest
    • Latest
    • News
    • North America
    • Europe
    • Asia
    • Middle East
    • Global
  • Coins2Day 500
    • Coins2Day 500
    • Coins2Day 500 U.S.
    • Coins2Day Global 500
    • Coins2Day 500 Europe
    • Coins2Day China 500
    • Coins2Day SEA 500
  • Finance
    • Finance
    • Economy
    • Banking
    • Personal Finance
    • Investing
    • Real Estate
    • Energy
    • Crypto
  • Tech
    • Tech
    • Big Tech
    • Startups & Venture
    • AI
    • Innovation
    • Cybersecurity
  • Leadership
    • Leadership
    • Future Of Work
    • Success
    • C-Suite
    • Workplace Culture
    • CEO Initiative
  • Lifestyle
    • Lifestyle
    • Arts & Entertainment
    • Health
    • Travel & Leisure
    • Education
  • Rankings
    • Rankings
    • Great Place To Work
    • Analytics
  • Multimedia
    • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Press Releases
    • Video
    • Podcasts
  1. home
  1. home
  2. Pharmaceutical Industry

Pharmaceutical Industry

Page 83 of 100

J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
Finance

Biotech Stocks Crashed and Nobody Knows Why

By Jen Wieczner
January 29, 2016
Key Speakers At The 2015 Dell World Conference
Features

New Barbie and Microsoft Earnings—5 Things to Know Today

By Tom Huddleston Jr. and Geoffrey Smith
January 28, 2016
Obama Speaks Before Leaving COP21
Leadership

You’ll Never Guess Who’s Blocking Obama’s FDA Nominee

By Ben Geier
January 26, 2016
Johnson & Johnson Products Ahead Of Earnings
Health

Drug Sales Are Driving Johnson & Johnson’s Growth

By Laura Lorenzetti
January 26, 2016
The Food and Drug Administration
Health

This Cough Syrup Was Recalled Because It Contains Morphine

By Chris Matthews
January 22, 2016
Martin Shkreli, CEO Reviled for Drug Price Gouging, Arrested on Securities Fraud Charges
Health

Martin Shkreli Is Headed For a Major Showdown With Congress

By Reuters
January 22, 2016
BRITAIN-PHARMACEUTICAL-GSK
Finance

Five Charged in U.S. With Stealing Secrets From GlaxoSmithKline

By Reuters
January 21, 2016
Senate Permanent Subcommittee On Investigations Hearing On U.S. Corporate Tax Code
Health

Valeant Vows to Make Its Drugs ‘Affordable’

By Laura Lorenzetti
January 13, 2016
Biosimilars Are Coming After Big Pharma’s Bottom Line
Health

Biosimilars Are Coming After Big Pharma’s Bottom Line

By Laura Lorenzetti
January 12, 2016
AbbVie Inc. To Buy Shire For $54.8 Billion
Health

Drugmaker Shire Is Buying Baxalta for $32 Billion

By Reuters
January 11, 2016
Pfizer In Merger Talks With Allergan PLC
Health

Pfizer Just Jacked Up Prices for All of These Drugs

By Reuters
January 9, 2016
AbbVie Inc. To Buy Shire For $54.8 Billion
Health

Shire’s Merger With Baxalta Merger Is Nearly Done

By Reuters
January 8, 2016
<> at Downsview Park on September 20, 2015 in Toronto, Canada.
Arts & Entertainment

Wu-Tang’s RZA Says He Doesn’t Care What Martin Shkreli Does with His Album

By Laura Lorenzetti
January 6, 2016
New York Mets v Washington Nationals
Arts & Entertainment

Why These Baseball Stars Are Suing Al Jazeera

By Michal Addady
January 6, 2016
Senate Permanent Subcommittee On Investigations Hearing On U.S. Corporate Tax Code
Health

Valeant Appoints Howard Schiller Interim CEO

By Reuters
January 6, 2016

Most Popular

  • Economy
    Trump may have shot himself in the foot at the Fed, as Powell could stay on while Miran resigns from White House post
    By Eleanor Pringle
  • Investing
    Tech stocks go into free fall as it dawns on traders that AI has the ability to cut revenues across the board
    By Jim Edwards
  • Success
    In 2026, many employers are ditching merit-based pay bumps in favor of ‘peanut butter raises’
    By Emma Burleigh
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • MPW
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms of Use
  • Single Issues for Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work at Coins2Day
  • Diversity and Inclusion
  • Terms and Conditions
  • Site Map

© 2026 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.